

CPR	Afdeling
Vejledning: Ved start af 1. linie KT/HER2-rettet terapi udfyldes On-study delen af skemaet. Endvidere bør off-study skema for den primære brystkræft være udfyldt med lokalisation af recidiv. Ved ophør af 1. linie KT/HER2-rettet terapi udfyldes Off-study delen af dette skema. For kombinationen Trastuzumab + Pertuzumab er indberetning obligatorisk.	

On-study

Recidiv	Dato								
	<table border="1" style="width: 100%; height: 20px;"> <tr> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> </tr> </table>								
1.Linie Kemoterapi									
1: Epirubicin 2: Docetaxel 3: Paclitaxel 4: Vinorelbine 5: Gemcitabine 6: Capecitabine 7: Eribulin 8: Anden									
Type <input type="checkbox"/> Hvis 8, angiv: _____	Startdato								
	<table border="1" style="width: 100%; height: 20px;"> <tr> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> </tr> </table>								
1.Linie HER2 rettet terapi									
1: Trastuzumab 2: Pertuzumab 3: Trastuzumab+Pertuzumab 4: Anden									
Type <input type="checkbox"/> Hvis 4, angiv: _____	Startdato								
	<table border="1" style="width: 100%; height: 20px;"> <tr> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> </tr> </table>								

Off-study

Behandling afsluttet	Dato								
Kemoterapi afsluttet	<table border="1" style="width: 100%; height: 20px;"> <tr> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> </tr> </table>								
HER2-rettet terapi afsluttet	<table border="1" style="width: 100%; height: 20px;"> <tr> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> </tr> </table>								
Primære årsag for HER2 <input type="checkbox"/>									
1: Patient død 2: Progression 3: Bivirkninger 4: Patientens ønske 5: Lægens beslutning									
6: Lost to follow up 7: Ændring af behandling 8: Anden, angiv: _____									
Seneste kontakt	Dato								
	<table border="1" style="width: 100%; height: 20px;"> <tr> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> </tr> </table>								
Bedste respons <input type="checkbox"/>	1: CR 2: PR 3: SD 4: PD 5: NE 6: ND								
	Dato for progression								
	<table border="1" style="width: 100%; height: 20px;"> <tr> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> </tr> </table>								
Død <input type="checkbox"/>	0: Nej 1: Ja								
	Dato død								
	<table border="1" style="width: 100%; height: 20px;"> <tr> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> <td style="width: 12.5%;"></td> </tr> </table>								